Interaction between human lymphoblastoid interferon and chemotherapeutic agents in vitro.
The combined effect of human lymphoblastoid interferon (HLBI) and anticancer agents on the growth of MOLT-4 was studied in vitro. The interferon showed a strikingly synergistic interaction in combination with aclarubicin, cytosine arabinoside or prednisolone. It was moderately synergistic in combination with adriamycin or 5-fluorouracil and tended to show additive effects with daunorubicin or vincristine. In vitro studies of combination chemotherapy with interferon and anticancer agents should yield valuable information as to the best combination for man.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes; D002330:Carmustine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004261:DNA Replication / Q000187:drug effects; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D066298:In Vitro Techniques; D007370:Interferon Type I / Q000627:therapeutic use*; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008727:Methotrexate / Q000627:therapeutic use; D013601:T-Lymphocytes
D000970:Antineoplastic Agents; D007370:Interferon Type I; D003561:Cytarabine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002330:Carmustine; D008727:Methotrexate